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Introduction
Knowledge of the effectiveness of cardioprotective
medication in women with suspected ischemia is ham-
pered by limited clinical trial data and heterogeneous
risk. We assessed the effectiveness of cardioprotective
medical treatment in women while adjusting for disease
severity determined by cardiovascular magnetic reso-
nance imaging (CMRI).
Hypothesis
Effectiveness of cardioprotective medication will be
evident in women at elevated risk determined by CMRI.
Methods
Women (n=113), mean age 58±12 years, undergoing
coronary angiography for symptoms suggestive of myo-
cardial ischemia additionally underwent myocardial per-
fusion and cardiac function CMRI evaluation. Previously
we identified four ischemic heart disease components
associated with adverse cardiac events: 1) coronary
artery stenosis > 50%, 2) low global myocardial perfu-
sion, 3) high cardiac energy utilization, and 4) myocar-
dial wall thickness > 10 mm. The latter three disease
components were measured using CMRI. Women were
stratified into 5 groups based on number of ischemic
heart disease components (0-4). Self-reported medica-
tion use included angiotensin converting enzyme inhibi-
tors, beta blockers (BB), calcium channel antagonists
(CCA) and nitrates. During follow-up (32±17 months)
time to first adverse event (death, myocardial infarction,
hospitalization for either congestive heart failure or for
worsening anginal symptoms) was analyzed. Cox pro-
portional hazard regression was performed to examine
the cardioprotective effectiveness of medications when
accounting for ischemic heart disease severity.
Results
Medication usage did not differ across ischemic heart
disease strata. Ischemic heart disease stratification pre-
dicted adverse cardiac events (hazard ratio 2.1, 95% con-
fidence interval 1.5-2.9, p<0.001) and the medication
combination of a BB or CCA and no nitrate were inde-
pendently associated with reduced risk of events (hazard
ratio 0.35, 95% confidence interval 0.14-0.86, p<0.05).
The model remained significant after adjustment for age
and Framingham risk score.
Conclusions
Using a combined model of ischemic heart disease sever-
ity and medication use, the medication combination of
beta-blocker or calcium antagonist and no nitrate were
associated with a decreased risk of adverse cardiac events
in women. Further investigation of these results should
be done with a prospective randomized clinical trial.
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